Experimental cholesterol cuts the risk of heart attack with ‘convenient’ dose once a day

A new daily pill could provide an easier and more convenient way to reduce cholesterol and reduce heart attack and the risk of stroke.

The experimental medicine, called ObiceTrapib, underwent a phase 3 clinical trial at Monash University in Australia.

The trial included more than 2,500 people with an average of 65 years of age. All had been diagnosed with heart disease or had genetically high cholesterol, according to a university press release.

This basic element of cheap pantry could be key to reducing cholesterol, suggests new research

All participants were receiving “maximum tolerated doses” of therapy to reduce cholesterol.

One group received ObiceTrapib and another group took a placebo, while maintaining their existing cholesterol drugs.

After 12 weeks, participants who take the new medicine showed a 32.6% reduction in LDL cholesterol and a 33.5% drop in lipoprotein (A) [Lp(a)]the declared launch.

The findings were presented last month at the European Congress of the Atherosclerosis Society in the United Kingdom and were also published in the New England Journal of Medicine.

The risk of heart disease of women could predict up to 30 years in advance with a blood test, discovers the study

“We know that many people with high risk of heart attack or stroke do not obtain their cholesterol levels low enough, even in the best available treatments,” said the main professor of the study Stephen Nicholls, director of the Victorian Heart Institute of the University of Monash and the Victorian Heart Hospital of the Monash Health, in the statement.

“We know that many people with high risk of heart attack or stroke do not obtain their cholesterol levels low enough, even in the best available treatments.”

“ObiceTrapib offers a new promising option: not only LDL cholesterol lowered by more than 30%, but we also saw a reduction in LP (A), which is much more difficult to treat and has been related to the increased risk of heart disease.”

Low density lipoprotein (LDL), which is sometimes called “bad cholesterol”, is associated with negative health effects when present in large quantities.

LDL can accumulate in blood vessels and increase heart attack and the risk of stroke, the researchers warned.

Click here to get the News application

Lipoprotein (A), or LP (A), is a protein that is known to increase the possibilities of a heart attack when present at high levels in the blood.

Unlike LDL, LP (a) is an inherited risk factor that cannot be modified with healthy behaviors or medications.

The participants discovered that ObiceTrapib was “well tolerated.”

“This could be a valuable tool in the fight against heart disease,” Nicholls added. “It is convenient, it is effective and can help close the gap for patients who have run out of options.”

Click here to register in our health newsletter

The study, which was funded by Newamsterdam Pharma, an ObiceTrapib developer based in the Netherlands, had some limitations, the researchers said.

For example, participants were not chosen based on LP (a), which means that the study did not determine how the drug hit those with high levels of the protein.

In addition, the study evaluated changes in LDL levels, but did not measure the real results of heart attack or stroke.

For more health articles, visit www.Newsnews.com/health

More studies are needed to follow patients for longer periods of time and include more diverse cohorts, researchers recognized.

News Digital contacted researchers for additional comments.